OBJECTIVES: A prospective, randomized, open-label study was conducted to evaluate effects on mammographic density in postmenopausal and late perimenopausal women receivingcontinuous combined or sequential combined hormone replacement therapy (HRT). METHODS: The subjects were randomized to treatment with low-dose continuous combined HRT containing 1 mg 17beta-estradiol plus 0.5 mg norethisterone acetate (Activelle) or a sequential combined HRT regimen consisting of 0.625 mg conjugated equine estrogens for 28 days plus 5 mg medrogestone for 14 days (Presomen). Mammograms were obtained at baseline and after 9 cycles (each 28 days) of treatment. RESULTS: The majority of women (approximately two-thirds in each treatment group) had no changes in mammographic breast density between baseline and the final study visit. There were no marked differences between treatment groups. Approximately 20% of women in both groups had a slight increase in mammographic density. Only 10-14% of women in both groups had a pronounced increase in mammographic density. The analyses of the degree of change showed no remarkable differences between treatments. CONCLUSION: These results indicate that the increase in mammographic density with a low-dose continuous combined HRT regimen is no greater than that with a sequential combined HRT regimen. The type of progestogen does not have an impact on the extent of mammographic density changes.
RCT Entities:
OBJECTIVES: A prospective, randomized, open-label study was conducted to evaluate effects on mammographic density in postmenopausal and late perimenopausal women receiving continuous combined or sequential combined hormone replacement therapy (HRT). METHODS: The subjects were randomized to treatment with low-dose continuous combined HRT containing 1 mg 17beta-estradiol plus 0.5 mg norethisterone acetate (Activelle) or a sequential combined HRT regimen consisting of 0.625 mg conjugated equine estrogens for 28 days plus 5 mg medrogestone for 14 days (Presomen). Mammograms were obtained at baseline and after 9 cycles (each 28 days) of treatment. RESULTS: The majority of women (approximately two-thirds in each treatment group) had no changes in mammographic breast density between baseline and the final study visit. There were no marked differences between treatment groups. Approximately 20% of women in both groups had a slight increase in mammographic density. Only 10-14% of women in both groups had a pronounced increase in mammographic density. The analyses of the degree of change showed no remarkable differences between treatments. CONCLUSION: These results indicate that the increase in mammographic density with a low-dose continuous combined HRT regimen is no greater than that with a sequential combined HRT regimen. The type of progestogen does not have an impact on the extent of mammographic density changes.
Authors: Seungyoun Jung; Frank Z Stanczyk; Brian L Egleston; Linda G Snetselaar; Victor J Stevens; John A Shepherd; Linda Van Horn; Erin S LeBlanc; Kenneth Paris; Catherine Klifa; Joanne F Dorgan Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-04 Impact factor: 4.254
Authors: Diana S M Buist; Melissa L Anderson; Susan D Reed; Erin J Aiello Bowles; E Dawn Fitzgibbons; Juleann C Gandara; Deborah Seger; Katherine M Newton Journal: Ann Intern Med Date: 2009-06-02 Impact factor: 25.391
Authors: Xuan Huang; Gina Reye; Konstantin I Momot; Tony Blick; Thomas Lloyd; Wayne D Tilley; Theresa E Hickey; Cameron E Snell; Rachel K Okolicsanyi; Larisa M Haupt; Vito Ferro; Erik W Thompson; Honor J Hugo Journal: Front Cell Dev Biol Date: 2020-07-14